| scholarly article | Q13442814 |
| P50 | author | Riku Kiviranta | Q114389913 |
| Ilpo M O Koskivirta | Q114389914 | ||
| Burkhard Kleuser | Q59916784 | ||
| Eero I Vuorio | Q114389726 | ||
| P2093 | author name string | Jean Vacher | |
| Roland Baron | |||
| Sutada Lotinun | |||
| Lynn Neff | |||
| William C Horne | |||
| Takuma Matsubara | |||
| Anja Lüth | |||
| Jorge A Alzate | |||
| P2860 | cites work | Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling | Q24319108 |
| RANK is essential for osteoclast and lymph node development | Q24598872 | ||
| Catabolic and anabolic actions of parathyroid hormone on the skeleton | Q26828873 | ||
| Matrix-embedded cells control osteoclast formation | Q28247746 | ||
| Evidence for osteocyte regulation of bone homeostasis through RANKL expression | Q28247757 | ||
| Pycnodysostosis, a lysosomal disease caused by cathepsin K deficiency | Q28284581 | ||
| A nonsense mutation in the cathepsin K gene observed in a family with pycnodysostosis | Q28297820 | ||
| Bidirectional signaling through ephrinA2-EphA2 enhances osteoclastogenesis and suppresses osteoblastogenesis | Q28510537 | ||
| Synaptotagmin VII regulates bone remodeling by modulating osteoclast and osteoblast secretion | Q28512093 | ||
| Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee | Q29616160 | ||
| NFATc1 in mice represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism | Q30157499 | ||
| Deletion of membrane-bound steel factor results in osteopenia in mice | Q31153361 | ||
| Bone density, strength, and formation in adult cathepsin K (-/-) mice | Q33374935 | ||
| FoxO-mediated defense against oxidative stress in osteoblasts is indispensable for skeletal homeostasis in mice | Q33645103 | ||
| Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey | Q34082585 | ||
| Intravenous bisphosphonate therapy for osteoporosis: where do we stand? | Q36203266 | ||
| Anti-Mac-1 selectively inhibits the mouse and human type three complement receptor | Q36347029 | ||
| I{kappa}B kinase (IKK){beta}, but not IKK{alpha}, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss | Q36402985 | ||
| Emerging roles of cysteine cathepsins in disease and their potential as drug targets. | Q36740577 | ||
| Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice | Q36791739 | ||
| Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. | Q37015968 | ||
| TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation | Q37307155 | ||
| Bone marrow-derived cathepsin K cleaves SPARC in bone metastasis | Q37316559 | ||
| c-Cbl and Cbl-b act redundantly to protect osteoclasts from apoptosis and to displace HDAC6 from beta-tubulin, stabilizing microtubules and podosomes | Q37346002 | ||
| Bisphosphonate associated osteonecrosis of the jaw. | Q37415072 | ||
| Femoral cortical stress lesions in long-term bisphosphonate therapy: a herald of impending fracture? | Q37681262 | ||
| Guidelines for assessment of bone microstructure in rodents using micro-computed tomography | Q37763651 | ||
| Cathepsin K: its skeletal actions and role as a therapeutic target in osteoporosis | Q37889119 | ||
| Human osteoblast-derived factors induce early osteogenic markers in human mesenchymal stem cells. | Q39994432 | ||
| Proteolytic processing and polarized secretion of tartrate-resistant acid phosphatase is altered in a subpopulation of metaphyseal osteoclasts in cathepsin K-deficient mice | Q40086345 | ||
| Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts | Q42520796 | ||
| An improved high-performance liquid chromatographic method for the determination of sphingosine-1-phosphate in complex biological materials | Q43563517 | ||
| The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis | Q44590934 | ||
| Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide | Q44663247 | ||
| Decreased body weight in young Osterix-Cre transgenic mice results in delayed cortical bone expansion and accrual | Q45730145 | ||
| Impaired gastric acidification negatively affects calcium homeostasis and bone mass. | Q46008246 | ||
| Human osteoblasts produce cathepsin K. | Q46282719 | ||
| A theoretical analysis of long-term bisphosphonate effects on trabecular bone volume and microdamage | Q46329107 | ||
| Complete genomic structure of the mouse cathepsin K gene (Ctsk) and its localization next to the Arnt gene on mouse chromosome 3. | Q47955419 | ||
| Mouse cathepsin K: cDNA cloning and predominant expression of the gene in osteoclasts, and in some hypertrophying chondrocytes during mouse development | Q48060056 | ||
| Targeted expression of Cre recombinase in macrophages and osteoclasts in transgenic mice. | Q50775674 | ||
| Balicatib, a cathepsin K inhibitor, stimulates periosteal bone formation in monkeys. | Q51496187 | ||
| Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. | Q51801651 | ||
| A RANKL G278R mutation causing osteopetrosis identifies a functional amino acid essential for trimer assembly in RANKL and TNF | Q57184035 | ||
| Cathepsin K Knockout Mice Develop Osteopetrosis Due to a Deficit in Matrix Degradation but Not Demineralization | Q57272396 | ||
| Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis | Q57675131 | ||
| Pycnodysostosis: refined linkage and radiation hybrid analyses reduce the critical region to 2 cM at 1q21 and map two candidate genes | Q71235368 | ||
| Quantitative measurement of sphingosine 1-phosphate in biological samples by acylation with radioactive acetic anhydride | Q71597850 | ||
| Characterization of osteoclast precursors in human blood | Q73309559 | ||
| Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio | Q81304554 | ||
| Odanacatib reduces bone turnover and increases bone mass in the lumbar spine of skeletally mature ovariectomized rhesus monkeys | Q82663650 | ||
| Osteoblast isolation from murine calvaria and long bones | Q82751283 | ||
| The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking | Q84479083 | ||
| Cathepsin K inhibitors prevent bone loss in estrogen-deficient rabbits | Q84795050 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 666-681 | |
| P577 | publication date | 2013-01-16 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation | |
| P478 | volume | 123 |
| Q36832193 | A RANKL-PKCβ-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts |
| Q87093819 | Activating cathepsin K in osteoclasts stimulates bone formation through S1P |
| Q37177840 | Advances in the regulation of osteoclasts and osteoclast functions |
| Q34577904 | Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB. |
| Q97422600 | Aging and menopause reprogram osteoclast precursors for aggressive bone resorption |
| Q55019978 | An Optimized Method to Generate Human Active Osteoclasts From Peripheral Blood Monocytes. |
| Q26774874 | Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review |
| Q33901933 | Aptamer-functionalized lipid nanoparticles targeting osteoblasts as a novel RNA interference-based bone anabolic strategy. |
| Q37673469 | Bone biology and anabolic therapies for bone: current status and future prospects |
| Q38598049 | Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies. |
| Q38843253 | Bone metastasis: the importance of the neighbourhood. |
| Q94673370 | Bone-Targeting AAV-Mediated Gene Silencing in Osteoclasts for Osteoporosis Therapy |
| Q34383078 | Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts |
| Q90642673 | Calcium Homeostasis: A Potential Vicious Cycle of Bone Metastasis in Breast Cancers |
| Q38666521 | Cathepsin K Inhibitors for Osteoporosis: Biology, Potential Clinical Utility, and Lessons Learned |
| Q49387831 | Cathepsin K Localizes to Equine Bone In Vivo and Inhibits Bone Marrow Stem and Progenitor Cells Differentiation In Vitro |
| Q38784335 | Cathepsin K osteoporosis trials, pycnodysostosis and mouse deficiency models: Commonalities and differences |
| Q90435509 | Cathepsin K regulates localization and secretion of Tartrate-Resistant Acid Phosphatase (TRAP) in TRAP-overexpressing MDA-MB-231 breast cancer cells |
| Q92185702 | Cathepsin K-deficient osteocytes prevent lactation-induced bone loss and parathyroid hormone suppression |
| Q52595231 | Cepharanthine Prevents Estrogen Deficiency-Induced Bone Loss by Inhibiting Bone Resorption. |
| Q90263630 | Coupling factors involved in preserving bone balance |
| Q37506724 | Coupling the activities of bone formation and resorption: a multitude of signals within the basic multicellular unit |
| Q36511687 | Curcumin improves bone microarchitecture in glucocorticoid-induced secondary osteoporosis mice through the activation of microRNA-365 via regulating MMP-9. |
| Q91958357 | Deficiency of sphingosine-1-phosphate receptor 3 does not affect the skeletal phenotype of mice lacking sphingosine-1-phosphate lyase |
| Q36784369 | Deletion of Rac in Mature Osteoclasts Causes Osteopetrosis, an Age-Dependent Change in Osteoclast Number, and a Reduced Number of Osteoblasts In Vivo. |
| Q28303937 | Differentially expressed genes in autosomal dominant osteopetrosis type II osteoclasts reveal known and novel pathways for osteoclast biology |
| Q37177303 | Disruption of c-Kit Signaling in Kit(W-sh/W-sh) Growing Mice Increases Bone Turnover |
| Q37283464 | Dynamic Cross Talk between S1P and CXCL12 Regulates Hematopoietic Stem Cells Migration, Development and Bone Remodeling |
| Q64886195 | EPC-derived exosomes promote osteoclastogenesis through LncRNA-MALAT1. |
| Q42563360 | Effects of estrogen depletion and drug treatment on collagen microstructure: implications |
| Q92604759 | Eldecalcitol effects on osteoblastic differentiation and function in the presence or absence of osteoclastic bone resorption |
| Q26782109 | Emerging Therapies for Osteoporosis |
| Q34219161 | Factors and mechanisms involved in the coupling from bone resorption to formation: how osteoclasts talk to osteoblasts |
| Q90451142 | Friend or Foe? Essential Roles of Osteoclast in Maintaining Skeletal Health |
| Q26764854 | From disease to treatment: from rare skeletal disorders to treatments for osteoporosis |
| Q37687674 | Glucocerebrosidase 2 gene deletion rescues type 1 Gaucher disease |
| Q55072999 | High Plasma Sphingosine 1-phosphate Levels Predict Osteoporotic Fractures in Postmenopausal Women: The Center of Excellence for Osteoporosis Research Study. |
| Q35755147 | High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes |
| Q38183262 | Implications of osteoblast-osteoclast interactions in the management of osteoporosis by antiresorptive agents denosumab and odanacatib. |
| Q46762020 | Increased sphingosine-1-phosphate production in response to osteocyte mechanotransduction |
| Q45763186 | Involvement of sphingosine 1-phosphate in palmitate-induced insulin resistance of hepatocytes via the S1P2 receptor subtype |
| Q35754345 | Kcnn4 is a regulator of macrophage multinucleation in bone homeostasis and inflammatory disease |
| Q34111708 | Loss of Cbl-PI3K interaction in mice prevents significant bone loss following ovariectomy |
| Q91405277 | Lupus-like Disease in FcγRIIB-/- Mice Induces Osteopenia |
| Q36926240 | Macrophages: Their Emerging Roles in Bone. |
| Q27022580 | Modulating Bone Resorption and Bone Formation in Opposite Directions in the Treatment of Postmenopausal Osteoporosis |
| Q37195704 | Modulation of IL-6 induced RANKL expression in arthritic synovium by a transcription factor SOX5 |
| Q26851553 | Modulation of osteoclast differentiation and bone resorption by Rho GTPases |
| Q35953074 | Mutation in Osteoactivin Promotes Receptor Activator of NFκB Ligand (RANKL)-mediated Osteoclast Differentiation and Survival but Inhibits Osteoclast Function |
| Q91688877 | New Insights on Properties and Spatial Distributions of Skeletal Stem Cells |
| Q35878795 | OPG Treatment Prevents Bone Loss During Lactation But Does Not Affect Milk Production or Maternal Calcium Metabolism |
| Q35033184 | Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial |
| Q35589110 | Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women |
| Q39190775 | Osteoblast-osteoclast interactions |
| Q36593362 | Osteoclast TGF-β Receptor Signaling Induces Wnt1 Secretion and Couples Bone Resorption to Bone Formation. |
| Q54782216 | Osteoclast depletion with clodronate liposomes delays fracture healing in mice. |
| Q36674531 | Osteoclast-derived exosomal miR-214-3p inhibits osteoblastic bone formation |
| Q89555393 | Osteoclast-mediated bone resorption is controlled by a compensatory network of secreted and membrane-tethered metalloproteinases |
| Q37123948 | Osteoclast-secreted CTHRC1 in the coupling of bone resorption to formation |
| Q51765760 | Osteoclast-secreted SLIT3 coordinates bone resorption and formation. |
| Q90056276 | Osteoclasts are not a source of SLIT3 |
| Q37036135 | Osteoclasts-Key Players in Skeletal Health and Disease |
| Q33993757 | Osteoclasts: more than 'bone eaters'. |
| Q34474147 | PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis |
| Q55082811 | Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts. |
| Q35027916 | Periostin deficiency increases bone damage and impairs injury response to fatigue loading in adult mice |
| Q90616784 | Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures |
| Q46114833 | Proceedings of the 2015 Santa Fe Bone Symposium: Clinical Applications of Scientific Advances in Osteoporosis and Metabolic Bone Disease. |
| Q35595132 | Proteomic study of different culture medium serum volume fractions on RANKL-dependent RAW264.7 cells differentiating into osteoclasts |
| Q37738764 | Rab27A regulates transport of cell surface receptors modulating multinucleation and lysosome-related organelles in osteoclasts. |
| Q50215136 | Recent advances in osteoclast biology. |
| Q48528045 | Regulation of Bone Remodeling by Parathyroid Hormone |
| Q37505505 | Regulation of lysosome biogenesis and functions in osteoclasts |
| Q57792100 | Regulatory mechanisms of sclerostin expression during bone remodeling |
| Q30619787 | Retinoid X receptors orchestrate osteoclast differentiation and postnatal bone remodeling |
| Q38849982 | Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice |
| Q34898865 | Runx2-Smad signaling impacts the progression of tumor-induced bone disease |
| Q91782570 | S1P-S1PR1 Signaling: the "Sphinx" in Osteoimmunology |
| Q38271410 | Sphingolipid metabolism and its role in the skeletal tissues |
| Q47881999 | Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair. |
| Q33795328 | Sphingosine 1-phosphate signaling in bone remodeling: multifaceted roles and therapeutic potential |
| Q92164563 | Sphingosine is able to prevent and eliminate Staphylococcus epidermidis biofilm formation on different orthopedic implant materials in vitro |
| Q90187449 | Sphingosine-1-phosphate (S1P) receptors: Promising drug targets for treating bone-related diseases |
| Q57399036 | Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss |
| Q28546666 | The Crosstalk between Osteoclasts and Osteoblasts Is Dependent upon the Composition and Structure of Biphasic Calcium Phosphates |
| Q98177574 | The Osteocyte as the New Discovery of Therapeutic Options in Rare Bone Diseases |
| Q87474598 | The circulating sphingosine-1-phosphate level predicts incident fracture in postmenopausal women: a 3.5-year follow-up observation study |
| Q90044719 | The emerging role of IMD 0354 on bone homeostasis by suppressing osteoclastogenesis and bone resorption, but without affecting bone formation |
| Q40828040 | The role of biochemical of bone turnover markers in osteoporosis and metabolic bone disease: a consensus paper of the Belgian Bone Club. |
| Q50848501 | The role of the progressive ankylosis protein (ANK) in adipogenic/osteogenic fate decision of precursor cells. |
| Q41995909 | Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis |
| Q92686596 | Whole-exome sequencing identified a novel variant in an Iranian patient affected by pycnodysostosis |
| Q36593417 | Wnt Signaling Inhibits Osteoclast Differentiation by Activating Canonical and Noncanonical cAMP/PKA Pathways |
Search more.